SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck

Phase 2

Completed

• Conditions: Carcinoma of Unknown Primary; Head and Neck Cancer; Non-melanomatous Skin Cancer

• Registration Number: NCT00006361
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck.

Detailed Description

OBJECTIVES:

* Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck.

* Determine the safety and toxicity of SU5416 in these patients.

OUTLINE: Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed for 1 year.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1.4 years.

Study Timeline

• Study First Submitted: 2000-10-04
• Study Start: 2000-12
• Status Verified: 2002-12
• Primary Completion: 2003-01
• Study First Submitted QC: 2003-05-29
• Study First Posted: 2003-05-30
• Last Update Submitted: 2009-12-03
• Last Update Posted: 2009-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Memorial Sloan-Kettering Cancer Center; 🇺🇸 New York, New York, United States